BioCryst   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Durham NC United States (1986)

Organization Overview

First Clinical Trial
1999
NCT00002237
First Marketed Drug
2014
peramivir (rapivab)
First NDA Approval
2014
peramivir (rapivab)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BIOCRYST | BioCryst Pharmaceuticals | BIOCRYST PHARMACEUTICALS INC